FOUNDERS

Dr. Gary Madsen: Co-Founder, President and CEO

Gary Madsen, Ph.D., has over 30 years of experience in developing and launching biotechnology products in a wide variety of markets at companies of various sizes.   He spent 17 years at Abbott Laboratories in product support, new product development and business development.  He was recruited to IDEXX Labs in Westbrook, Maine as Vice President of Research and Development.

In addition to the positions at Abbott Labs and IDEXX Labs, he has held executive positions at EraGen Biosciences (Chief Technical Officer), Promega Corp. (Director of Product and Business Development), Third Wave Technologies (Associate Vice President, Automation), Gilson Inc. (Senior Vice President, Strategic Business Development), and Biotech Resolutions, LLC (Founder).

His past successes include the development and launch of numerous regulated new products, leadership of large cross-functional teams, development and implementation of strategic plans, and consulting with a wide variety of biotech companies on critical strategic issues.

In 2012 he joined UNeMed as Entrepreneur In Residence and relocated to Omaha, NE from Madison, WI.  Growing out of that role was the formation of ProTransit Nanotherapy and ProTransit Dermal Therapy with Dr. Vinod Labhasetwar in April and May, respectively, of 2013.

Dr. Madsen presented a basic overview of the company and its strategy to the local TV and radio stations following a press release regarding the licensing agreement between UNeMed and ProTransit Nanotherapy.  More recently, the company was featured in an Omaha World Herald article on UNeMed.

KETV:  UNMC specialists develop cutting edge sunblock lotion

KLIN radio: KLIN Radio Podcast

Dr. Vinod Labhasetwar, Co-Founder and CSO

Vinod Labhasetwar, Ph.D., is a Professor in the Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.  His expertise is in translational/clinical nanomedicine in the area of cancer, CNS injuries, and cardiovascular diseases. His current research focus is on a) cancer detection and treatments using surface engineered nanoparticles for drug and gene delivery, b) antioxidant enzyme delivery to the central nervous system to prevent reperfusion injury in stroke and to treat spinal cord injury, and c) vascular targeting of therapy to prevent post-angioplasty hyperplasia.

His basic research interest is to understand the role of biophysics of cell membrane lipids in drug transport and nanoparticle uptake. His recent work involves investigating epigenetic nanotherapy for treating drug resistant and metastatic cancers. He has published over 160 peer-reviewed articles and holds several U.S. and international patents.  He has received awards as a Young Scientist, Distinguished Scientist, and Innovator. He is a Fellow of the American Association of Pharmaceutical Scientists. Thomson Reuters in 2014 listed him Highly Cited Researcher based on top 1% by citation (2002 to 2012) and Most Influential Mind in Science.  Dr. Labhasetwar is awarded Mahatma Gandhi Pravasi Samman Gold Medal for his contribution in Science and Technology at a function held at House of Lords, London, UK on Oct 9, 2014. Dr. Labhasetwar is the founding editor-in-chief of Drug Delivery and Translational Research, an official journal of the Controlled Release Society.